Term
|
Definition
| alpha-1 D-Ag; BP under anesthesia; short duration mydriasis; nasal decongestant; for acute hypotension |
|
|
Term
|
Definition
| alpha-2 D-Ag; Tx HT;opiate withdrawal; decrease BP in CNS |
|
|
Term
|
Definition
| beta-1,2 D-Ag;increase in CO + decrease in MAP; brief duration (COMT); for emergency cardiac arrest or heart block. |
|
|
Term
|
Definition
| beta-1 D-Ag; D1,2 Ag; short duration (MOA; COMT) increase renal/mesenteric bld. flow; natriureisis (D1); Vomiting (D2); NE release (NET substrate); vasoconstriction (alpha-1); for cardiogenic shock |
|
|
Term
|
Definition
| beta-1 D-Ag; short duration; no DA-R activation; for cardiogenic shock |
|
|
Term
|
Definition
| beta-2 D-Ag; can be administered sub-q; rapid onset, short duration; delay labor |
|
|
Term
|
Definition
| beta-2 D-Ag; rapid onset, short duration; prevents HISTAMINE release from mast cells |
|
|
Term
|
Definition
| beta-2; prophylaxis of exercise-induced asthma; slow onset, long duration |
|
|
Term
|
Definition
| beta-2 D-Ag; uterine relaxant, delay labor |
|
|
Term
|
Definition
| I-Ag; blocks NET; reverse NE transport; oral; BBB penetration; for narcolepsy, ADHD |
|
|
Term
|
Definition
| I-Ag; structural analog of amphetamine; for ADHD |
|
|
Term
|
Definition
| I-Ag; increases NE in synapse; short t1/2; alpha-1, beta-2 D-Ag; for asthma, enuresis, nasal decongestion |
|
|
Term
|
Definition
| I-Ag; increases NE in synapse; alpha-1 D-Ag; for nasal decongestion |
|
|
Term
|
Definition
| I-Ag; releases catecholamines; in food; byproduct of Tyr metabolism; short t1/2 (MAO) |
|
|
Term
|
Definition
| I-Ag; blocks NET; powerful CNS stimulant; DA reuptake inhibitor; |
|
|
Term
| MAOi (Phenelzine); COMTi (Entacapone) |
|
Definition
| I-Ag; prevents secondary NE deamination after reuptake; for depression and Parkinson's respectively (decreases DA degradation = increased levadopa t1/2) |
|
|
Term
|
Definition
| catecholamine synthesis inhibitor; inhibits Tyr hydroxylase; for pheochromocytoma |
|
|
Term
|
Definition
| catecholamine synthesis inhibitor; inhibits aromatic L-amino acid decarboxylase; blocks levadopa-->DA in PNS = levadopa into CNS; + levadopa for Parkinson's |
|
|
Term
|
Definition
| non-selective alpha Antag.; irreversible; decreases BP (reflexive tachycardia and increased CO); increses NE release; tissue responsiveness restored when new receptors made; for preoperative management of pheochromocytoma and Reynaud's |
|
|
Term
|
Definition
| non-selective alpha Antag.; reversible; decreases BP (reflexive increase in CO and tachycardia); for BP control during pheochromocytoma and erectile dysfunction |
|
|
Term
|
Definition
| reversible alpha-1 Antag.; decreases vascular resistance (for peripheral vascular disease/Reynaud's) and venous return (for HT); relaxes prostatic sm. mm. (BPH); decreases LDLs and TGs, increases HDLs. |
|
|
Term
|
Definition
| reversible alpha-1 Antag.; water soluble and high bioavailability; for HT and BPH |
|
|
Term
|
Definition
| reversible alpha-1 Antag.; long duration; for HT and BPH |
|
|
Term
|
Definition
| reversible alpha-1 Antag.; relaxes prostatic sm. mm; short duration; |
|
|
Term
|
Definition
| reversible alpha-2 Antag. = NE release; for hypotension; reverse HT effects of clonidine; little clinical value |
|
|
Term
|
Definition
| non-selective beta blocker; reduces HR, BP, renin; highly lipophilic (for migraine); liver metabolized (first pass); for ischemic heart disease |
|
|
Term
|
Definition
| non-selective beta blocker; reduces HR, BP, renin; less lipid soluble, NO local anesthetic effect; for open angle glaucoma (decreases aq. humor secretion) |
|
|
Term
|
Definition
| non-selective beta blocker, competitive alpha-1 Antag., beta-2 agonist; reduces HR, BP, renin; local anesthetic; for HT (alpha-1 block + beta-2 agonist = vasodilation) |
|
|
Term
|
Definition
| non-selective beta blocker, alpha-1 Antag.; NO local anesthetic effect; for CHF and myocardial infarction |
|
|
Term
|
Definition
| beta-1 blocker; drop in HR, BP, and contractility; NO local anesthetic effect, for HT, angina and arrhythmia |
|
|
Term
|
Definition
| beta-1 blocker; drop in HR, BP, and contractility; local anesthetic; first pass; for HT, heart failure, and arrythmia |
|
|
Term
|
Definition
| beta-1 blocker; drop in HR, BP, and contractility; short t1/2; NO local anesthetic effect; for tachycardia, arrhythmia, HT, thyroid storm |
|
|
Term
|
Definition
| direct acting cholinergic agonist; = parasympathetic stimulation; brief duration (AChE); vasodilation, miosis, near vision, glandular secretion, bronchial constriction, bradycardia, GI activity |
|
|
Term
|
Definition
| direct acting cholinergic agonist; less hydrolysis; cardiovascular-selective; reduces HR, contractility, contraction vel., for asthma diagnosis |
|
|
Term
|
Definition
| direct acting cholinergic agonist; bladder and GI tract; mAChR-selective; very resistant to hydrolysis; |
|
|
Term
|
Definition
| direct acting cholinergic agonist; nAChR-selective; depolarizing blockade desensitization = muscle paralysis; Phase1/2 block; metabolized by pseudoChE in plasma |
|
|
Term
|
Definition
| direct acting cholinergic agonist; mAChR-selective; very resistant to hydrolysis; reduces HR, contractility, and conduction vel. |
|
|
Term
|
Definition
| direct acting cholinergic agonist; not used clinically; toxicity if enters CNS |
|
|
Term
|
Definition
| direct acting cholinergic agonist; nAChR-selective; can be absorbed across skin; will desensitize; CNS stimulant |
|
|
Term
|
Definition
| direct acting cholinergic agonist; mACHR-selective; well absorbed |
|
|
Term
|
Definition
| carbamate indirect cholinergic agonist; also nAChR agonist; intermediate duration of action; for Myasthenia Gravis, slow Alzheimer's |
|
|
Term
|
Definition
| carbamate indirect cholinergic agonist; crosses BBB; for anticholinergic poisoning |
|
|
Term
|
Definition
| organophosphate indirect cholinergic agonist; irreversible conjugate with AChE (longest duration); well absorbed (skin, gut, lungs); crosses BBB; insecticides |
|
|
Term
|
Definition
| simple alcohol indirect cholinergic agonist; reverses muscle weakness in pts with Myasthenia Gravis only |
|
|
Term
|
Definition
| naturally occurring antimuscarinic; inverse agonist; well absorbed (gut and conjunctiva); crosses BBB; potent against salivary, bronchial, and sweat glands; for cholinergic poisoning, reversal of sinus bradycardia, and reduce secretions during surgery, prolonged midriasis (also cycloplegic) |
|
|
Term
|
Definition
| naturally occurring antimuscarinic; fast onset; crosses skin and BBB; for motion sickness, to reduce secretions during surgery |
|
|
Term
|
Definition
| synthetic antimuscarinic; for asthma and COPD |
|
|
Term
|
Definition
| synthetic antimuscarinic; for peptic ulcers (M1-selective: autonomic ganglia and CNS) |
|
|
Term
|
Definition
| synthetic antimuscarinic; M3-selective (smooth mm. and glands); for urinary incontinence |
|
|
Term
|
Definition
| alpha-2 Ag.; does NOT cross BBB (minimal systemic effect); for OAG |
|
|
Term
|
Definition
| mAChR Antag.; mydriasis and cycloplegia; 1 day duration; for OAG |
|
|
Term
|
Definition
| mAChR Antag.; mydriasis and cycloplegia; 5-6 hrs duration (shortest); for OAG |
|
|
Term
|
Definition
| alpha-2 Ag; decrease in aq. secretion and increased outflow; crosses BBB; for OAG |
|
|
Term
|
Definition
| ganglionic blocker; inhibits autonomic postganglionic AChR (competitive); IV-admin; for hypertensive emergencies |
|
|
Term
|
Definition
| ganglionic blocker; blocks channel after opening; inhibits autonomic postganglionic R; for HT |
|
|
Term
|
Definition
| ganglionic blocker; inhibits autonomic postganglionic R; crosses BBB |
|
|
Term
|
Definition
| nondepolarizing neuromuscular blocker; Cholinergic Antag.; doesn't cross BBB; for reducing dosage of anesthesia during surgery |
|
|
Term
|
Definition
| nondepolarizing neuromuscular blocker; potent and less likely to cause histamine release; most widely used muscle relaxant; short duration (25-45 min); not dependent on renal or hepatic function; for relaxation during surgery |
|
|
Term
|
Definition
| nondepolarizing neuromuscular blocker; |
|
|
Term
|
Definition
| nondepolarizing neuromuscular blocker; 5x more potent than tubocurarine; elimination by liver; very short duration (35 min) |
|
|
Term
|
Definition
| nondepolarizing neuromuscular blocker; rapid onset; shortest duration (10-20 min); metabolized by pseudocholinesterase |
|
|
Term
|
Definition
| spasmolytic; facilitates GABA binding to GABA-A-R; opens Cl- channels; inhibits SC primary afferents; for chronic spasm from cerebral palsy, muscle injury, spinal cord injury |
|
|
Term
|
Definition
| spasmolytic; GABA-B-receptor Ag.; increased K+ conductance, inhibits substance P release; orally active; for pain reduction (intrathecal admin., for spasticity due to cerebral palsy, MS, stroke. |
|
|
Term
|
Definition
| spasmolytic; inhibits Ca2+ release; binds to ryanodine R (disrupts excitation-contraction coupling); for malignant hyperthermia |
|
|
Term
|
Definition
| spasmolytic; inhibits ACh release at presynaptic terminals (cleaves SNARE); duration of weeks and months; for spastic disorders, face wrinkles, strabismus |
|
|
